A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization

Figures

• 

  Figure 1. Respondents’ indication of the first-choice P2Y12 inhibitor in all acute coronary syndrome clinical settings. (A): Indication of the first-choice P2Y12 inhibitor in ST-segment elevation myocardial infarction (STEMI). (B): Indication of the first-choice P2Y12 inhibitor in non ST-segment elevation myocardial infarction (NSTEMI). (C): Indication of ticagrelor percentage of use in NSTEMI conservatively managed.

• 

  Figure 2. (A): Overall utilization of scores in clinical practice. (B): Main scores utilized in clinical practice overall. (C): Main scores utilized in clinical practice to estimate ischemic risk (%). (D): Main scores utilized in clinical practice to estimate bleeding risk (%).

• 

  Figure 3. Most relevant elements considered in order to prolong DAPT at 12 months.

• 

  Figure 4. Main barriers to long-DAPT prescription in post-MI CCS patients in clinical practice.

• 

  Figure 5. Possible actions aimed at the implementation of follow-up and cure in post-MI CCS patients.